Elumn8 Medical

Executive Summary

Elumn8 Medical is a privately held medical device company headquartered in Irvine, California, dedicated to revolutionizing the treatment of coronary chronic total occlusions (CTOs). CTOs represent one of the most technically challenging subsets of coronary artery disease, with current percutaneous coronary intervention (PCI) success rates limited by the inability to reliably cross the occlusion. The company's lead product, the Acolyte™ System, is a novel combination imaging and crossing device designed to simplify the CTO PCI procedure, potentially increasing procedural success while reducing complication rates and procedure time. Founded in 2018, Elumn8 addresses a significant unmet need in interventional cardiology, as CTOs affect a substantial proportion of patients with coronary artery disease and are often left untreated due to the complexity and risk involved. The CTO PCI market is underserved, with few dedicated devices and a high reliance on operator skill. Elumn8's Acolyte System has the potential to standardize the procedure and broaden the pool of operators capable of performing CTO interventions. The company benefits from its location in Irvine, a hub for medical device innovation, and is positioned to attract strategic partnerships or investment to advance clinical development. While still in early stages, the technology's promise could capture significant market share if proven effective in clinical studies.

Upcoming Catalysts (preview)

• H2 2026Completion of First-in-Human Study70% success
• Q3 2026FDA Breakthrough Device Designation80% success
• Q4 2026Series A Funding Round60% success